Healthcare | February 04, 2022
Sir HN Reliance Foundation Hospital partners with Karkinos Healthcare for community cancer screening
The target demographic will be those between the ages of 30 and 65 years
The target demographic will be those between the ages of 30 and 65 years
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Owkin builds best-in-class predictive biomedical AI models and robust data sets
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
